<DOC>
	<DOCNO>NCT02434744</DOCNO>
	<brief_summary>This study compare safety , tolerability efficacy combination KD026 metformin compare placebo metformin improve glycemic control patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Study KD026 Combination With Metformin Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Have type 2 diabetes , finger stick HbA1c ≥ 7.0 % ≤ 11.0 % screen visit , HbA1c via venipuncture ≥ 7.0 % ≤ 11.0 % Qualification visit Have metformin least 12 week prior screen visit metformin dose expect change 4week runin period Have BMI ≥ 27 kg/m2 ≤ 45 kg/m2 Men , postmenopausal woman ( defined menstrual period least 1 year ) , surgically sterile woman ( least 1 year ) , woman childbearing potential negative pregnancy test within last 24 hour Women childbearing potential men whose partner childbearing potential must agree use two form accept method contraception course study 1 month last dose study drug . Effective birth control include ( ) IUD plus one barrier method ; ( b ) stable dos hormonal contraception least 3 month ( eg , oral , injectable , implant , transdermal ) plus one barrier method ; ( c ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) ; ( ) vasectomize partner Have type 1 diabetes Taking antidiabetic medication addition metformin Have fast plasma glucose &gt; 270 mg/dL screen visit Have serum creatinine ≥1.7 mg/dL glomerular filtration rate &lt; 60 mL/min screen visit Have history diabetic retinopathy Uncontrolled high blood pressure Have history chronic liver disease and/or alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 2.0 × upper limit normal ( ULN ) screen visit . Have history malignant cancer ( basal cell , localized cervical , squamous cell carcinoma skin remove ) Have history presence gastrointestinal ( GI ) disease major gastrointestinal surgery , opinion investigator , could interfere drug absorption Currently use prohibit medication stop Abuse alcohol ( defined average weekly intake great 21 unit average daily intake great 3 unit [ 1 unit equivalent half pint beer , 1 serve hard liquor , one glass wine ] History presence drug abuse accord Diagnostic Statistical Manual Mental Disorders V ( DSMV ) criterion within 2 year prior screen visit Have 12lead ECG screen visit , opinion investigator , abnormality may compromise safety study , include QTc ( F ) interval ( QT interval data correct use Fridericia 's formula ) &gt; 450 msec Have clinically significant abnormal laboratory result include thyroidstimulating hormone ( TSH ) &gt; 1.5 × ULN screen visit Have positive test hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody/virus ( HCV ) human immunodeficiency virus ( HIV ) antibodies screen visit document history positive result Pregnant lactate woman Previously receive KD026 ( formerly name SLx4090 ) Participated trial investigational drug within 4 week prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>